Vasopermeability enhancing immunoconjugates

Details Vasopermeability enhancing immunoconjugates Vasopermeability enhancing immunoconjugates

1995-04-10

1999-12-28

Stucker, Jeffrey

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

435 696, 435 7021, 4351722, 4351723, 4241551, 4241741, 4241831, 4241801, 530350, 530380, 530382, 5303871, 5303881, 5303888, 53038885, 5303911, 5303913, A61K 39395, C12P 2104, C12N 1500, C07K 100

Patent

active

060078170

ABSTRACT:
Conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. The vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a drug, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally affected.

REFERENCES:
patent: 4101380 (1978-07-01), Rubenstein et al.
patent: 4110432 (1978-08-01), Wilkinson et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4673573 (1987-06-01), Ferres et al.
patent: 4724212 (1988-02-01), Epstein
patent: 4724213 (1988-02-01), Epstein
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4843147 (1989-06-01), Levy et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5061626 (1991-10-01), Baldo et al.
patent: 5241078 (1993-08-01), Moreland et al.
Cater et al., "Inflammatory Changes in Tumour Vessels after Systemic 5-Hydroxytrptamine, Bradykinin, Kallikrein, or Lysolecithin," in Tumour Vascularity and Inflammatory Mediators (1967).
Dvorak et al., Am J. Path, 133:95-109 (1988).
Obrist et al., in Int. J. Immunopharm, 5:307-314 (1983).
Cellular Immunology, 81:169-174 (1983).
Biochem, Biophys. Res. Comm., 155:1139-1144 (1988).
Pelham et al., Cancer Immunol. Immunother., 15:210-216 (1983).
Flannery et al., Eur. J. Cancer Clin., Oncol., 20:514-517 (1985).
Vogel et al., Haematology and Blood Transfusion, 29:514-517 (1985).
Vogel, "Antibody Conjugates without Inherent Toxicity: The Targeting of Cobra Venom Factor and other Biological Response Modifiers" in Immunoconjugates (C. Vogel, ed.), pp. 170-188 (1987).
Levy and Miller, Fed. Proc. 42:2650-56 1983.
Foon et al. Blood 64:1085-1093 1984.
Sears, et al. Cancer Res. 45:5910-5913 1985.
De Nardo, S. et al. Nucl. Med. Biol. 13:303-10 1986.
Hurwitz, E. et al. Cancer Res. 35:1175-81 1975.
Ghose, T. et al. J. Natl. Cancer Inst. 58:845-52 1977.
Vogel, C. and Muller-Eberhard, H. PNAS-USA 78(12):7707-11.
Vogel, C. et al. Hematology and Blood Transfusion Modern Trends in Human Leukemia VI 29:514-17 Neth et al. eds Berlin 1985.
Flannery, G. et al. Eur. J. Cancer Clin. Oncol. 20(6):791-798 1984.
Obrist, R. et al. Blut 53:251 1986.
Obrist, R. and Sandburg, A. Cellular Imun. 81:169-74 1983.
Lowder et al. Blood 69:199-210 1987.
Epenetos et al. Cancer Res. 46:3183-91 1986.
Kaelin, N. et al. Cancer Res. 44:896-99 1984.
Thomlinson, P. and Gray, L. British J. Cancer 9:539-549 1955.
Sands et al. Cancer Res. 48:188-93 1988.
Bomber, P. et al. J. Nucl. Med. 27:243-45 1986.
Kohler and Milstein Nature 256:495 1975.
McFarlane, A. Biochem. J. 62:135-143 1956.
Epstein, A. et al. Malignant Lymphomas and Hodgkins Disease: Expla. and Th'ptc. Advcs. Martinus Nijoff Publ. Co. Boston 1985 pp. 569-577.
Wilbanks et al. Cancer 48:1768-75 1981.
Wahl et al. J. Nucl. Med. 24:315-325 1983.
Porter, R. Biochem J. 73:119 1959.
Lembeck, F. and Halzer, P. Naunyn-Schmeideberg's Arch. Pharmacol. 310:175-83 1979.
Erspamer, V. TINS Nov. 1981 pp. 267-269.
Hagermark, O. et al. J. or Invest. Dermatology 71:233-235 1978.
Nagata, S. et al. Int. Archs. Allergy Appl. Immun 82:4-9 1987.
Hugli, T. and Erickson, B. PNAS-USA 74:1826-30 1977.
Kampschmidt, R. J. Leukocyte Biol. 36:341-55 1984.
Fairman, R. et al. Cancer Res. 47:3528-32 1987.
Rosenstein et al. J. of Immunol. 1735-42 1986.
Talmadge et al. Cancer Res. 47:2563-70 1987.
Philip, R. and Epstein, L. Nature 323:86-89 1986.
Antoni, G. et al. J. of Immunol. 137:3201-04 1986.
Turnbull, L. et al. Immunology 32:57-63 1977.
Okano, Y. et al. Fed. Europ. Biochem. Soc. 185(2):363-66 1985.
Hirai, Y. et al. Chem. Pharm. Bull. 27(8):1942-44 1979.
Serafin, W. and Austin, K. New England J. of Med., Jul. 2, 1987 pp. 30-34.
Braquet, P. and Rola-Pleszezynski, M. Immunol. Today 8(11):345-52 1987.
Chan, et al. J. of Hypertension 4(6):741-746 1986.
Birnbaum et al. J. Medicinal Chem. 25(5):492-94 1982.
Glovsky, M. et al. J. of the Reticuloendthelial Society 33:401-13 1983.
Sherwood, E. et al. J. of Biological Response Modifiers 7:185-98 1988.
Goodfriend, T. et al. Science 144:1344-46 1964.
Carlsson, J. et al. Biochem J. 173:723-737 1978.
Shen, W.C., Ryser, H. Biochem. Biophys. Res. Comm 102(3):1048-1054 1981.
Kitao, T. and Hattori, K. Nature 265:81-82 1977.
Smyth, M. et al. J. Natl. Cancer Inst. 76(3):503-10 1986.
Bindon et al. Brit. J. Cancer 47:123-133 1983.
Seon, B. Cancer Res. 44:259-64 1984.
Taniguchi, T. Nature 302:305-10 1983.
Ziltener, H.J. et al. J. Immunol 138:1099-1104 1987.
Eisenthal, et al., Cancer Res. 48 (24) Part 1: 7140-45 (1988).
Eisenthal, et al., Chem. Abst. 109: 527, Abst. No. 90913w (1988).
Kawase, et al., Cancer Res. 48(5): 1173-79 (1988).
Sands, et al., Cancer Res. 48: 188-193 (1988).
Sherwood, et al., J. Biol. Resp. Modif. 7(2): 185-198 (1988).
Philip, et al., Nature 323: 86-89 (1986).
Smyth, et al., JNCI 76(3): 503-510 (1986).
Burger, et al., Chem. Abst. 109: 511, Abst. No. 127053u (1988).
Obrist, et al., Cellular Immunology 81:169-174, 1983.
Obrist, et al., Blut 53:251, 1986, Abstract No. 243.
Osband et al., Immunology Today 11(6):193-195, 1990.
Waldmann, T.A., Science 252:1657-1662, Jun. 21, 1991.
Dillman, R.O., Annals of Internal Medicine 111:592-603, 1989.
Hird et al, in Genes and Cancer, Corney et al, Eds., Wiley & Sons, pp. 183-189, 1990.
Sands et al., "Correlation of Vascular Permeability and Blood Flow with Monoclonal Antibody Uptake by Human Clouser and Renal Cell Xenografts," Cancer Research 48:188-193, Jan. 1, 1988.
Bomber et al., "Propanolol Hydrochloride Enhancement of Tumor Perfusion and Uptake of Gallium-67 in a Mouse Sarcoma," J. Nucl. Med. 27:243-245, Feb. 1986.

Affiliated with

Also associated with

Rating

Vasopermeability enhancing immunoconjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vasopermeability enhancing immunoconjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vasopermeability enhancing immunoconjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2380490